title: SLV-308. Solvay.
abstract: Solvay is developing SLV-308 (SME-308), a partial dopamine D2 agonist and noradrenergic agonist with serotonin 5-HT1A agonist properties, for the potential oral treatment of Parkinson's disease (PD), panic and depression. By January 2001, SLV-308 had entered phase II trials for PD and phase I trials for anxiety and depression.
authors: Hines VA Hospital, Loyola University Chicago School of Medicine, Hines, IL 60141, USA. William.Wolf@med.va.gov
authors: William A
authors: WA
authors: Wolf
mesh_terms: D000818:Animals; D000978:Antiparkinson Agents / Q000138:chemical synthesis / Q000627:therapeutic use*; D001583:Benzoxazoles / Q000737:chemistry / Q000627:therapeutic use; D002986:Clinical Trials as Topic / Q000706:statistics & numerical data; D015507:Drugs, Investigational / Q000138:chemical synthesis / Q000627:therapeutic use*; D006801:Humans; D010300:Parkinson Disease / Q000188:drug therapy*; D010879:Piperazines / Q000737:chemistry / Q000627:therapeutic use; D013678:Technology, Pharmaceutical / Q000379:methods
chemical_list: D000978:Antiparkinson Agents; D001583:Benzoxazoles; D015507:Drugs, Investigational; D010879:Piperazines; C480679:pardoprunox